Neuroscience News and Research

RSS

A&A journal achieves significant increase in Impact Factor; reflects scientific value of medical journals

Anesthesia & Analgesia (A&A), official journal of the International Anesthesia Research Society (IARS), has achieved a significant increase in its Impact Factor, a key indicator of the influence and scientific value of medical journals, the IARS announced today.

29 Jun 2010

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.

28 Jun 2010

National Intrepid Center of Excellence to treat veterans with traumatic brain injury

The U.S. Department of Defense and the Intrepid Fallen Heroes Fund on June 24 officially dedicated the National Intrepid Center of Excellence, a new 72,000-square-foot medical facility in Bethesda, Md., dedicated to researching, diagnosing and treating traumatic brain injury in U.S. military personnel.

28 Jun 2010

Athersys, CSCRM and CWRU receive $1M to advance MultiStem therapy for SCI

Athersys, Inc. and its collaborators, including the Center for Stem Cell and Regenerative Medicine and Case Western Reserve University, announced today that they have been awarded $1 million through the Ohio Third Frontier Biomedical Program to support research into the treatment of spinal cord injury with MultiStem, Athersys' proprietary stem cell product candidate.

25 Jun 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

Brain scanning study has implications for advertising and public health campaigns

In a study with implications for the advertising industry and public health organizations, UCLA neuroscientists have shown they can use brain scanning to predict whether people will use sunscreen during a one-week period even better than the people themselves can.

25 Jun 2010

MDS Nordion, Guerbet, Cyceron collaborate to develop new PET radiotracers for cancer diagnostics

MDS Nordion, a leading provider of products and services to the global health science market, Guerbet, a pharmaceutical group specialized in medical imaging, and Cyceron, a biomedical imaging centre in France, announced today they have entered into an agreement to develop new Positron Emission Tomography (PET) radiotracers for cancer diagnostics.

24 Jun 2010

Boston Scientific launches SCS lead splitters for use with Precision Plus Spinal Cord Stimulator System

Boston Scientific Corporation today announced U.S. Food and Drug Administration approval and launch of two spinal cord stimulation (SCS) lead splitters for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk, back and/or limbs.

24 Jun 2010

Group of tests may help predict falls in people with Parkinson's disease: Study

A group of tests may help predict which people with Parkinson's disease are more likely to fall, according to a study published in the June 23, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

24 Jun 2010

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

AstraZeneca and Targacept, Inc., today announced the enrollment of the first patient in the Phase 3 clinical development program for TC-5214, a nicotinic channel blocker.

23 Jun 2010

Researchers study why the brain of newborn baby is particularly flexible

Science has long puzzled over why a baby's brain is particularly flexible and why it easily changes. Is it because babies have to learn a lot? A group of researchers from the Bernstein Network Computational Neuroscience, the Max Planck Institute for Dynamics and Self-Organization in G-ttingen, the Schiller University in Jena and Princeton University have now put forward a new explanation: Maybe it is because the brain still has to grow.

23 Jun 2010

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo.

23 Jun 2010

UCL scientists explain Parkinson's disease patients' ICBs

Scientists at UCL have explained Parkinson's patients' risky behaviour, a rare side effect of standard treatments for the disease. The finding has implications for future medication of patients.

23 Jun 2010

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Neurologix, Inc., today announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson's disease, NLX-P101. Study participants who received NLX-P101 experienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to control subjects who received sham surgery.

22 Jun 2010

Antibody treatment could significantly improve lives following spinal cord injury: Researchers

The United States Department of Defense Spinal Cord Injury Research Program has announced a grant of more than a million dollars U.S. to support research at the Robarts Research Institute at The University of Western Ontario (Western). The spinal cord injury research team of Gregory Dekaban, Arthur Brown, Lynne Weaver and Paula Foster, in collaboration with Brian Kwon of the University of British Columbia and Kyle Petersen of the U.S. Naval Medical Research Center, is working on a new therapy designed to limit the damage caused by inflammation immediately following spinal cord injury.

22 Jun 2010

Omega-3 effective for treating depression in patients without anxiety disorders

The use of Omega-3 supplements is effective among patients with major depression who do not have anxiety disorders, according to a study directed by Dr. Fran-ois Lesp-rance of the Centre de recherche du Centre hospitalier at the Universit- de Montr-al (CRCHUM), head of CHUM's Department of Psychiatry and a professor at the Universit- de Montr-al. The study was published June 15 in the online Journal of Clinical Psychiatry.

22 Jun 2010

Millar, Telemetry Research partner to offer TRM53P implantable transmitters

Millar Instruments, Inc., a medical device manufacturing firm and developer of pressure sensing technology, has released the TRM53P implantable transmitter through the partnership with Telemetry Research, Ltd. The TRM53P is the world's first, fully implantable transmitter that combines Millar's gold standard solid-state pressure sensors with Telemetry Research's next generation telemetry technology.

21 Jun 2010

UCLA research sheds light on how brain tells time

The ability to tell time is fundamental to how humans interact with each other and the world. Timing plays an important role, for example, in our ability to recognize speech patterns and to create music. Patterns are an essential part of timing. The human brain easily learns patterns, allowing us to recognize familiar patterns of shapes, like faces, and timed patterns, like the rhythm of a song. But exactly how the brain keeps time and learns patterns remains a mystery.

21 Jun 2010

Serotonin transporter gene appears to increase one's risk for depression, PTSD: Study

There is a great deal of interest in factors that contribute to the vulnerability to developing post-traumatic stress disorder, or PTSD. One factor that appears to contribute to the heritable vulnerability to PTSD is a variation in the gene that codes for the serotonin transporter, also known as the serotonin uptake site. Having a shorter version of the serotonin transporter gene appears to increase one's risk for depression and PTSD after exposure to extremely stressful situations.

18 Jun 2010

Trial eases concerns over effects of gamma secretase inhibitors for Alzheimer's disease treatment

The first trial of a new model for testing Alzheimer's treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted.

18 Jun 2010

Neuroscience News and Research

A&A journal achieves significant increase in Impact Factor; reflects scientific value of medical journals

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

National Intrepid Center of Excellence to treat veterans with traumatic brain injury

Athersys, CSCRM and CWRU receive $1M to advance MultiStem therapy for SCI

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Brain scanning study has implications for advertising and public health campaigns

MDS Nordion, Guerbet, Cyceron collaborate to develop new PET radiotracers for cancer diagnostics

Boston Scientific launches SCS lead splitters for use with Precision Plus Spinal Cord Stimulator System

Group of tests may help predict falls in people with Parkinson's disease: Study

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

Researchers study why the brain of newborn baby is particularly flexible

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

UCL scientists explain Parkinson's disease patients' ICBs

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Antibody treatment could significantly improve lives following spinal cord injury: Researchers

Omega-3 effective for treating depression in patients without anxiety disorders

Millar, Telemetry Research partner to offer TRM53P implantable transmitters

UCLA research sheds light on how brain tells time

Serotonin transporter gene appears to increase one's risk for depression, PTSD: Study

Trial eases concerns over effects of gamma secretase inhibitors for Alzheimer's disease treatment

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News